Drug · CHEMBL553

ERLOTINIB

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. ERLOTINIB. Drugs and targets, record CHEMBL553. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL553

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: ERLOTINIB; ChEMBL
ChEMBL ID: CHEMBL553; ChEMBL
Type: Small molecule; ChEMBL
Other names: CP-358,774, CP-358774, CP-35877401, R-1415, RG-1415, Ro-508231; ChEMBL
Other form: ERLOTINIB HYDROCHLORIDE, CHEMBL1079742; Drugs and targets
DrugBank: DB00530; DrugBank
InChIKey: AAKJLRGGTJKAMG-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 4 of its 95 diseases, from ATC, EMA Human Drugs, PMDA and TTD; Open Targets

Targets1

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
EGFR	Epidermal growth factor receptor	Epidermal growth factor receptor erbB1 inhibitor	INHIBITOR	https://conductscience.org/library/genes/1956

Source ChEMBL

Diseases95

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
non-small cell lung carcinoma	Approval	EMA Human Drugs, PMDA and TTD	309	304	https://conductscience.org/library/drugs?q=MONDO_0005233
exocrine pancreatic carcinoma	Phase 3	ClinicalTrials.gov	30	30	https://conductscience.org/library/drugs?q=MONDO_0005192
pancreatic neoplasm	Approval	EMA Human Drugs	23	20	https://conductscience.org/library/drugs?q=MONDO_0021040
malignant pancreatic neoplasm	Phase 3	TTD	21	20	https://conductscience.org/library/drugs?q=MONDO_0009831
head and neck squamous cell carcinoma	Phase 3	ClinicalTrials.gov	19	19	https://conductscience.org/library/drugs?q=MONDO_0010150
breast cancer	Phase 2	ClinicalTrials.gov	17	17	https://conductscience.org/library/drugs?q=MONDO_0007254
colorectal cancer	Phase 3	ClinicalTrials.gov	17	17	https://conductscience.org/library/drugs?q=MONDO_0005575
pancreatic adenocarcinoma	Phase 3	ClinicalTrials.gov	16	16	https://conductscience.org/library/drugs?q=MONDO_0006047
lung adenocarcinoma	Phase 2	ClinicalTrials.gov	15	15	https://conductscience.org/library/drugs?q=MONDO_0005061
hepatocellular carcinoma	Phase 3	ClinicalTrials.gov	13	12	https://conductscience.org/library/drugs?q=MONDO_0007256

1 to 10 of 95Source Open Targets

See all 95 diseases

Trials612

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 10 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00949910	An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)	Phase 4	6,586	2016-10-04	erlotinib	Its name	ClinicalTrials.gov
NCT01996332	A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)	Phase 2	1,805	2014-07-10	erlotinib	Its name	ClinicalTrials.gov
NCT00364351	Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy	Phase 3	1,574	2011-05-24	erlotinib	Its name	ClinicalTrials.gov
NCT00373425	A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors	Phase 3	1,252	2014-06-03	erlotinib	Its name	ClinicalTrials.gov
NCT00257608	A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)	Phase 3	1,145	2016-03-15	erlotinib	Its name	ClinicalTrials.gov
NCT01244191	Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer	Phase 3	1,048	2020-10-30	erlotinib	Its name	ClinicalTrials.gov
NCT00457392	A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone	Phase 3	960	2011-08-02	erlotinib	Its name	ClinicalTrials.gov
NCT00556712	A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)	Phase 3	889	2015-02-11	erlotinib	Its name	ClinicalTrials.gov
NCT01360554	ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer	Phase 3	878	2017-05-24	erlotinib	Its name	ClinicalTrials.gov
NCT01523587	LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy	Phase 3	795	2014-11-21	erlotinib	Its name	ClinicalTrials.gov

1 to 10 of 612

See all 612 trials

Comparisons in its trials132

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Biomarker Cohort vs Non-biomarker Cohort: deaths from any cause	364 of 618	3,780 of 4,661	5,279	NCT05834348	Trial comparisons
Vandetanib vs Erlotinib: Objective Response Rate (ORR)	75 of 623	74 of 617	1,240	NCT00364351	Trial comparisons
Vandetanib vs Erlotinib: Disease Control Rate (DCR)	254 of 623	242 of 617	1,240	NCT00364351	Trial comparisons
Vandetanib vs Erlotinib: serious adverse events	197 of 623	155 of 614	1,237	NCT00364351	Trial comparisons
Tivantinib and Erlotinib vs Placebo and Erlotinib: deaths from any cause	77 of 520	65 of 517	1,037	NCT01244191	Trial comparisons
Tivantinib and Erlotinib vs Placebo and Erlotinib: serious adverse events	219 of 520	191 of 517	1,037	NCT01244191	Trial comparisons
Sunitinib + Erlotinib vs Erlotinib: serious adverse events	207 of 473	181 of 477	950	NCT00457392	Trial comparisons
Erlotinib, 150 mg/Day vs Placebo: serious adverse events	49 of 433	34 of 445	878	NCT00556712	Trial comparisons
Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo) vs Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo): serious adverse events	178 of 436	169 of 436	872	NCT01360554	Trial comparisons
Afatinib vs Erlotinib: Number of Participants With Disease Control According to RECIST 1.1	201 of 398	157 of 397	795	NCT01523587	Trial comparisons

1 to 10 of 132

See all 132 comparisons in its trials

Papers from its trials337

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39389055	RESULT	1	PubMed
33405269	RESULT	1	PubMed
32782544	RESULT	1	PubMed
31733490	RESULT	1	PubMed
31256737	RESULT	1	PubMed
30138764	RESULT	1	PubMed
29787357	RESULT	1	PubMed
29741745	RESULT	1	PubMed
28359318	RESULT	1	PubMed
28260924	RESULT	1	PubMed

1 to 10 of 337

See all 337 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL553

GET https://conductscience.org/api/drugs/v1/CHEMBL553/diseases?page=2

API reference For AI assistants